TY - JOUR
T1 - Design, Synthesis, and Biological Evaluation of Bivalent Ligands Targeting Dopamine D2 -Like Receptors and the μ-Opioid Receptor
AU - Qian, Mingcheng
AU - Vasudevan, Lakshmi
AU - Huysentruyt, Jelle
AU - Risseeuw, Martijn D P
AU - Stove, Christophe
AU - Vanderheyden, Patrick M L
AU - Van Craenenbroeck, Kathleen
AU - Van Calenbergh, Serge
N1 - © 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.
PY - 2018/5/8
Y1 - 2018/5/8
N2 - Currently, there is mounting evidence that intermolecular receptor-receptor interactions may result in altered receptor recognition, pharmacology and signaling. Heterobivalent ligands have been proven useful as molecular probes for confirming and targeting heteromeric receptors. This report describes the design and synthesis of novel heterobivalent ligands for dopamine D2 -like receptors (D2 -likeR) and the μ-opioid receptor (μOR) and their evaluation using ligand binding and functional assays. Interestingly, we identified a potent bivalent ligand that contains a short 18-atom linker and combines good potency with high efficacy both in β-arrestin 2 recruitment for μOR and MAPK-P for D4 R. Furthermore, this compound was characterized by a biphasic competition binding curve for the D4 R-μOR heterodimer, indicative of a bivalent binding mode. As this compound possibly bridges the D4 R-μOR heterodimer, it could be used as a pharmacological tool to further investigate the interactions of D4 R and μOR.
AB - Currently, there is mounting evidence that intermolecular receptor-receptor interactions may result in altered receptor recognition, pharmacology and signaling. Heterobivalent ligands have been proven useful as molecular probes for confirming and targeting heteromeric receptors. This report describes the design and synthesis of novel heterobivalent ligands for dopamine D2 -like receptors (D2 -likeR) and the μ-opioid receptor (μOR) and their evaluation using ligand binding and functional assays. Interestingly, we identified a potent bivalent ligand that contains a short 18-atom linker and combines good potency with high efficacy both in β-arrestin 2 recruitment for μOR and MAPK-P for D4 R. Furthermore, this compound was characterized by a biphasic competition binding curve for the D4 R-μOR heterodimer, indicative of a bivalent binding mode. As this compound possibly bridges the D4 R-μOR heterodimer, it could be used as a pharmacological tool to further investigate the interactions of D4 R and μOR.
KW - Cells, Cultured
KW - Dose-Response Relationship, Drug
KW - Drug Design
KW - HEK293 Cells
KW - Humans
KW - Ligands
KW - Molecular Probes/chemical synthesis
KW - Molecular Structure
KW - Polyethylene Glycols/chemical synthesis
KW - Receptors, Dopamine D2/agonists
KW - Receptors, Opioid, mu/agonists
KW - Structure-Activity Relationship
U2 - 10.1002/cmdc.201700787
DO - 10.1002/cmdc.201700787
M3 - Article
C2 - 29451744
VL - 13
SP - 944
EP - 956
JO - ChemMedChem
JF - ChemMedChem
SN - 1860-7179
IS - 9
ER -